Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Sean Beinart

Clinical Cardiac Electrophysiology Rockville, MD Medical Doctor

NPI 1083714661 CMS profile 48738

15225 Shady Grove Road, Suite 201, Rockville, MD 20850

Open in the dashboard

General payments

$315,212

708 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Research they led as principal investigator

$341,442 paid to institutions, not to them · program years 2019–2025

Through program year 2025, Sean Beinart of Rockville, MD is reported in the CMS Open Payments database as having received $315,212 across 708 general payments and $0 in research payments paid to them. Separately, studies naming them as principal investigator received $341,442 in research payments, paid to institutions rather than to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them. The principal-investigator line is research money paid to institutions for studies they led — not to them — and is not added to anything either.

General payments for this record sit in the 96th percentile of Clinical Cardiac Electrophysiology profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $3,470 78
2024 General $11,969 73
2023 General $20,503 68
2022 General $36,768 73
2021 General $57,223 129
2020 General $72,442 94
2019 General $112,838 193

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Sean Beinart
  • Clinical Cardiac Electrophysiology median
  • Middle half of Clinical Cardiac Electrophysiology
  • National median

In program year 2025, general payments to Sean Beinart were reported at $3,470. Among 3,064 Clinical Cardiac Electrophysiology profiles paid that year, the median was $2,462 and the middle half received between $733 and $7,710.

Show as a table
Year Sean Beinart Clinical Cardiac Electrophysiology median Middle half National median
2019 $112,838 $2,361 $585–$8,260 $163
2020 $72,442 $993 $247–$4,351 $114
2021 $57,223 $1,185 $326–$4,739 $132
2022 $36,768 $2,073 $554–$6,789 $149
2023 $20,503 $2,568 $759–$8,159 $160
2024 $11,969 $2,557 $703–$7,403 $164
2025 $3,470 $2,462 $733–$7,710 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Janssen Pharmaceuticals, Inc $83,498 102 payments
  2. Lundbeck LLC $61,028 63 payments
  3. Sanofi-Aventis U.S. LLC $56,154 37 payments
  4. Abbott Laboratories $37,097 140 payments
  5. ZOLL Services LLC (A/K/A ZOLL LifeCor Corp) $33,078 75 payments
  6. E.R. Squibb & Sons, L.L.C. $14,977 53 payments
  7. Pfizer Inc. $11,012 27 payments
  8. Philips Electronics North America Corporation $7,133 10 payments
  9. Medtronic Vascular, Inc. $3,731 15 payments
  10. Medtronic, Inc. $3,299 45 payments
  11. Other $4,205 141 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $184,109 87 payments
  2. Honoraria $53,880 21 payments
  3. Consulting Fee $31,574 17 payments
  4. Travel and Lodging $19,915 76 payments
  5. Food and Beverage $15,197 496 payments
  6. Compensation for serving as faculty or as a speaker for a non-accredited and noncertified continuing education program $10,450 10 payments
  7. Education $87 1 payment
Products named General payments · program years 2019–2025
  1. XARELTO $83,498 102 payments
  2. NORTHERA $61,005 62 payments
  3. LifeVest $33,078 75 payments
  4. MULTAQ Cardiology/Vascular Diseases $30,503 21 payments
  5. ELIQUIS Cardiovascular $14,765 40 payments
  6. MULTAQ Cardiology/Vascular Diseases $10,935 8 payments
  7. ELIQUIS Cardiovascular;Metabolic Disease $10,813 18 payments
  8. CVX-300 $6,800 4 payments
  9. Ensite Cardiac Mapping System $6,523 13 payments
  10. ADVISOR $6,050 2 payments
  11. Other $36,487 363 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 36 drugs

Part D claims

2,229

Median for Clinical Cardiac Electrophysiology: 1,090

Drug cost

$710,474

Median for Clinical Cardiac Electrophysiology: $354,841

Branded share of claims

30.3%

Median for Clinical Cardiac Electrophysiology: 38.3%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Eliquis Apixaban Brand 314 $397,148
Entresto Sacubitril/Valsartan Brand 72 $103,808
Xarelto Rivaroxaban Brand 79 $101,704
Multaq Dronedarone Hcl Brand 19 $31,005
Jardiance Empagliflozin Brand 24 $23,689
Repatha Sureclick Evolocumab Brand 20 $10,966
Farxiga Dapagliflozin Propanediol Brand 11 $7,545
Metoprolol Succinate Generic 332 $6,844
Dofetilide Generic 17 $3,025
Dabigatran Etexilate Dabigatran Etexilate Mesylate Brand 12 $3,001

The 10 drugs with the highest cost, of 36 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 2,573 Part D prescribers listed as Clinical Cardiac Electrophysiology; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 83 billing codes

Paid by Medicare

$476,814

Of which drugs: $1,213

Medicare patients

3,155

Average age 77

Services billed

9,030

1,721 women, 1,434 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 59%
Ischemic heart disease 46%
Atrial fibrillation 43%
Diabetes 40%
Heart failure 40%
Chronic kidney disease 37%
Depression 30%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Injection, regadenoson, 0.1 mg J2785 Office 50 200 $1,213

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 13 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
XARELTO
  • Janssen Pharmaceuticals, Inc $8,856
$8,856 79 —
JARDIANCE
  • Boehringer Ingelheim Pharmaceuticals, Inc. $206
$206 24 —
MULTAQ
  • SANOFI-AVENTIS U.S. LLC $70
$70 19 —
CAMZYOS
  • E.R. Squibb & Sons, L.L.C. $60
$60 — —
ENTRESTO
  • Novartis Pharmaceuticals Corporation $51
$51 72 —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 13 in the dashboard with a free account

Records

708 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Clinical Cardiac Electrophysiology in Maryland

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record